

Content available at: <https://www.ipinnovative.com/open-access-journals>

Indian Journal of Microbiology Research

Journal homepage: <https://www.ijmronline.org/>

Original Research Article

***In vitro* lytic efficacy of bacteriophages against multidrug-resistant pathogenic bacterial species isolated from pyogenic skin infections**Manjunath Nandihalli Shetru^{1,*}, Maribasappa Karched², Dayanand Aggar³, Rangaswamy B E¹¹Dept. of Biotechnology, Bapuji Institute of Engineering and Technology, Davangere, Karnataka, India²Oral Microbiology Research Laboratory, Faculty of Dentistry, Kuwait University, Kuwait³Dept. of Microbiology, Gulbarga University, Gulbarga, Karnataka, India

ARTICLE INFO

Article history:

Received 16-11-2021

Accepted 25-11-2021

Available online 11-04-2022

Keywords:

Antibiotics

Multidrug resistance

Skin infection

Bacteriophage therapy

ABSTRACT

Introduction: Bacterial multidrug resistance has worsened the situation by adding to economic burden but also poses a greater risk of patient death. The aim of the study was to characterize the multidrug resistance (MDR) properties of the bacterial isolates from skin infections and then to isolate and evaluate lytic efficacy of bacteriophages against the pathogenic bacteria.

Materials and Methods: Antimicrobial susceptibilities of the isolates (n=84) from pyogenic skin infections against 14 antibiotics was studied using CLSI guidelines. Phylogenetic analyses of the MDR strains from each species was performed. Lytic efficacy of the sewage-derived phages was assessed by spot test.

Results: *Staphylococcus aureus* was the most predominant (57, 68%) of the total of 84 isolates. The number of Gram-negative isolates that were resistant to all antibiotics (except amikacin) were significantly higher (P<0.05). On the other hand, significant number of *S. aureus* strains were susceptible only to clindamycin and erythromycin (P<0.05). Phylogenetic analysis based on the 16S rRNA gene revealed close relatedness of the strains with MDR strains previously reported. *In vitro* analysis of select MDR strains (n=20) showed that the bacteriophages ΦDMSA-2, ΦDMEC-1 and ΦDMPA-1 against *S. aureus*, *E. coli*, and *P. aeruginosa*, respectively, showed lytic efficacy against 4 of 5 MDR strains tested from each species.

Conclusions: These preliminary, but still important results emphasize the potential of phages as an effective alternative therapy against MDR bacteria. Further, the lytic efficacy of phages underscores the importance of developing need-based and locally isolated bacteriophages as potential antimicrobial therapy alternative to antibiotics.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Skin and soft tissue infections are a major healthcare issue worldwide and are of particular importance in developing countries.¹ Factors that exacerbate skin infection cases in the developing countries are low level of hygiene, lack of access to clean water, malnutrition, and overcrowded living conditions in lower socio-economic classes.²

* Corresponding author.

E-mail address: nsm.microb1973@gmail.com (M. N. Shetru).

Pyogenic bacteria such as *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Escherichia coli* and *streptococci* are the prominent species involved in intricate multibacterial infections of deeper skin structures, major abscesses, burns and ulcers, bite wounds and diabetic.³ Even though most skin infections begin as local induration, erythema, pain or tenderness at the site of infection, the impact may be so worse that it can progress to life-threatening necrotizing fasciitis. When a healthy skin encounters a

bacterial onslaught, epidermal cells (keratinocytes) stage robust innate immune response producing antimicrobial peptides and proinflammatory cytokines.⁴ However, with a progressing infection, pathogenic bacteria succeed in gaining entry to keratinocytes and evade host immune response. Since the majority of antibiotics cannot freely enter eukaryotic cells, cutaneous intracellular accumulation of pathogens like methicillin-resistant *S. aureus* (MRSA) poses a great challenge to treat skin infections using antibiotics.⁵ Further, the indiscriminate and reckless use of antibiotics has led to a crisis of multidrug resistance among bacterial pathogens. Infections caused by multidrug resistant microorganisms often fail to respond to conventional treatment, resulting in prolonged illness and greater risk of death. New resistance mechanisms have emerged in various bacteria, making the antibiotic therapy difficult.⁶ The longer duration of illness and treatment often in hospitals increases health-care costs and the economic burden to families and societies where it increases the costs of health care.⁷

During the recent past bacteriophage therapy has gained a renewed interest as a potential alternative therapy for multidrug-resistant (MDR) bacterial infections.⁸ Importantly, phages possess remarkable species specificity to bacterial pathogens. Further, an important clinical significance is that phage therapy can be very effective in biofilm infections where antibiotics fail to kill bacterial cells in biofilms, which are impermeable to antibiotics.⁹ Phage therapy finds special advantage for localized use, because phages penetrate deeper as long as the infection is present, rather than decrease rapidly in concentration below the surface. The phages stop reproducing once specific bacteria they target are destroyed. This prevents the development of secondary resistance to phages, which is quite often the case in antibiotics. Since phages live in the same niche as their host bacteria,¹⁰ and that they exhibit very high specificity (both species- and strain-specificity), it is crucial that phages are isolated and characterized for their bacteria-lytic ability locally in the affected regions. We recently demonstrated in an *in vivo* skin excisional wound model that the survival rate in mice was significantly high when a locally isolated phage against methicillin-resistant *S. aureus* was applied to the wounds.¹¹ In this study we took up a systematic approach at first to isolate clinically important pathogenic bacterial species from pyogenic skin infections, determined antibiotic susceptibility of the isolates and then tested phages for lytic efficacy against MDR bacterial pathogen isolates.

2. Materials and Methods

2.1. Collection of clinical samples

The study was approved by the institutional Ethics Committee (Institutional Animal Ethics Committee-IAEC, Sree Siddaganga College of Pharmacy, Tumkur,

Karnataka state, India-572 102 with an Approval reference No:SSCPT/IAEC.Clear/130/12-13). Written informed consent was obtained from all study patients (n=114). Swab samples from pyogenic skin infections were collected from patients of different age groups including males (n=82 median age 41 yrs) and females (n=32 median age 28 yrs). Swabs were immersed in 1% sterile peptone water and immediately subjected to microbial culture in aseptic conditions within 30-45 min of collection.

2.2. Isolation, identification and characterization of bacterial pathogens

The samples were at first cultured on general nutrient agar medium and suspect colonies were subsequently subcultured on selective agar media for different species. The major clinically important bacterial species from pyogenic infections were isolated using selective growth medium for each species. Identification of the species was achieved by extensive microbiological and biochemical characterization of presumptive colonies.

2.3. Antibiotic susceptibility of the bacterial isolates

The confirmed clinical isolates of each species were screened for antibiotic susceptibility by Kirby Bauer's disc diffusion method,^{12,13} according to Clinical and Laboratory Standard Institute (CLSI) guidelines (2005). Six hours old cultures were spread uniformly on the surface of Mueller-Hinton agar plates, antibiotic discs were placed on the agar surface and the plates were incubated at 37°C for 24 hr. The zone of inhibition was recorded in millimetres. The results were interpreted as susceptible or resistant as per the CLSI guidelines, 2005.¹⁴ Blank discs without antibiotic were used as negative controls in each experiment. The minimum inhibitory concentration (MIC) of methicillin was performed on *S. aureus* using the broth microdilution methods as described previously.¹⁵

2.4. DNA extraction, 16SrRNA gene amplification and phylogenetic analysis

Genomic DNA from the bacterial isolates was extracted by following a previously described method.¹⁶ Complete 16S rRNA gene from select strains from each species were amplified using the primers 16S-1-GGT GGA GCA TGT GGT TTA and 16S-2 (5'-16S-2 CCA TTG TAG CAC GTG TGT).¹⁷ PCR reaction mixture consisted of 200 μ M dNTPS, 2.5 U Taq DNA polymerase and DNA template. After thermal cycling, the PCR products were gel purified using the QIAquick PCR Purification Kit. Following a nested PCR strategy,¹⁷ a 256-bp internal region of the amplified 16S rRNA gene was sequenced with an ABI 3100 automated sequencer (Applied Biosystems). The sequence of the PCR product was compared with known 16S rRNA gene sequences in the Gene Bank by multiple sequence

alignment using the CLUSTAL W Program . Phylogenetic trees were constructed using Mega 5 program.

2.5. PCR amplification of *mecA* gene

To test whether the methicillin resistant *S. aureus* strains harbored a methicillin resistance gene (*mecA*), 4 of the MRSA isolates were subject to PCR by using the primers *mecA*-F (5'- CCT AGT AAA GCT CCG GAA) and *mecA*-R Primer (5'- CTA GTC CAT TCG GTC CA) as describe previously.¹⁸ The 25- μ l reaction mixture included 200 μ M dNTPs, 2.5 μ M primers, 2.5 U of Taq DNA polymerase. Thermal profile was as follows: Initial denaturation for 5 min at 94°C, followed by 30 cycles of denaturation for 30s at 94°C; annealing for 30s at 53°C; and primer extension for 40 sec at 72°C and a final extension for 10 min at 72°C. A 10- μ l PCR product was loaded onto a 1.2% agarose gel the bands were visualized under a UV transilluminator.

2.6. Isolation of bacteriophages

A cocktail of sewage originated from hospital, municipal and domestic waste in Davangere city, Karnataka, India, was used as a source for the isolation of phages. Initially, 25 ml of the cocktail sewage sample was pre-treated with 200 μ l of chloroform for 15 minutes and to this, 2 ml of 16-18 hours old bacterial cultures, each species separately, were added and incubated overnight at 37°C. The lysate was centrifuged (4000 \times g, 10 min) and the supernatant was filtered through a 0.22 μ m membrane filter and serially diluted using SM phage buffer. One hundred microliter from this stock was mixed with 100 μ l of host bacterial suspensions. Bacterial cell suspension without phage filtrate was used as a negative control. After incubation (37 °C, 20 min), luria bertani agar (0.7%) was added to the above, mixed gently and poured on LB agar plates followed by incubation at 37°C for 15-16 hours. A few prominent and isolated plaques were recovered using a sterile gel cutter followed by suction. The bacteriophage particles were diffused out of agarose by adding chloroform. The phage preparations were stored at 4°C for further use.

2.7. Transmission electron microscopy

Transmission electron microscopy was carried out at the laboratory of Hans-W Ackermann, Professor Emeritus, Department of Microbiology and Immunology, Laval University, Quebec, Canada. A high titer bacteriophage lysate of 10⁸ pfu ml⁻¹ previously filtered through 0.22 μ m Minisart Sartorius filter was centrifuged and treated with a fixative 1% glutaraldehyde. A drop of purified and fixed phage lysate was deposited on Formvar carbon-coated copper grids and negatively stained with 1% phosphotungstic acid (PTA). The grids were examined in Tecnai G² Biotwin (Philips-Netherlands) transmission electron microscope. The images of phages were captured

and the sizes of head and tail were measured.

2.8. Determination of Phage host range (Spot test)

Bacterial isolates (4 from each species) were screened for phage lysis by a spot test. The suspensions of log-phase bacteria were added to 15 ml sterile tubes with molten 3 ml agarose maintained at 47°C. The contents were mixed and overlaid on pre-dried LB agar plates. The dried plates having bacterial layer, on which 5 μ l of phage suspension (10⁸ pfu ml⁻¹) was dropped and incubated at 37°C without inverting the plates. The results were scored as a clear zone of complete lysis (++), partial lysis with turbidity (+) and no lysis (0).

2.9. Effect of storage period, pH, temperature and chloroform on the stability of the phages

The storage stability of the phages was determined at temperatures -40°C, -20°C, 4°C, and 20°C and also in presence of 20% (v/v) glycerol at -40°C and -20°C. Stability was also tested at pH 2, 4, 5, 6, 7, 8, 9 and 10. Phage titres were determined after 3, 6, 9 and 12 months of storage by double agar layer technique.

2.10. Statistics

Antibiotic resistance or susceptibility differences between the groups were determined using McNemar test. Differences in plaque titre values (pfu/ml) were determined using a non-parametric Mann-Whitney U test. A P value of < 0.05 was considered statistically significant. The statistical software SPSS version 25.0 (IBM Corp, Armonk, NY, USA) was used for all analyses.

3. Results

3.1. Bacterial pathogens from pyogenic skin infections

Among the 84 bacterial strains isolated from pyogenic skin infections of the study (Table 1), *S. aureus* was the most prevalent with 57 (67.85%) isolates followed by *P. mirabilis* 14 (16.66%), *P. aeruginosa* 7 (8.33%), *E. coli* 5 (5.95%) and *S. xylosum* 1 (1.19%). The highest prevalence of all bacteria (41, 48.80%) was recorded from abscess, followed by pyoderma (11, 13.09%), ulcers (9, 10.71%), cellulitis (5, 5.95%), wounds (5, 5.95%), diabetic foot (5, 5.95%), and post-operative infections (4, 4.76%). Only one *S. aureus* strain was isolated from burn wound infections.

3.2. Antibiotic susceptibility of the bacterial pathogens from pyogenic infections

All bacterial isolates (n=74) were subjected to antibiotic susceptibility testing (Table 2). *S. aureus* isolates were found to be resistant to most of the common antibiotics, with a highest (22/46, 48%) resistance for amikacin followed

by 40% (18/46 strains) of the strains for ciprofloxacin. However, clindamycin and erythromycin were the only antibiotics to which significantly higher number of *S. aureus* isolates were susceptible ($P < 0.05$). The single isolate from the *S. xyloso* species was sensitive to clindamycin and methicillin and resistant to all other antibiotics tested for Gram positive bacteria. From Gram negatives, significantly higher number of isolates were resistant to all the antibiotics tested except amikacin ($P < 0.05$). *P. aeruginosa* isolates were resistant 100% (10 of 10 strains) for amoxicillin, 80% (8/10) for cephalexin, 80% (8/10) for cefoperazone, 60% (6/10) and 40% for each of ceftazidime, ciprofloxacin, levofloxacin, tobramycin and amikacin respectively. *E. coli* isolates were resistant 50% (2/4) for amikacin and ceftazidime, 100% for cefoperazone (4/4), 75% (3/4) for each of the other antibiotics (Table 2).

3.3. Methicillin resistance among *S. aureus* strains

Considering the clinical significance of methicillin-resistant *S. aureus* strains, we also looked at the occurrence of MRSA strains among our *S. aureus* isolates. All strains of *S. aureus* having methicillin MIC of $> 4 \mu\text{g/ml}$ were considered methicillin-resistant. As evidenced by antibiotic susceptibility tests, 41% of all *S. aureus* isolates were found to be methicillin-resistant (Table 2). When a molecular confirmation of methicillin resistance in these strains was sought, 3 strains showed an amplicon corresponding to the size of *mecA* gene (Figure 1). Similar to isolates from other species, these MDR *S. aureus* strains were selected for investigating the host range of the bacteriophage $\Phi\text{DMSA-2}$.




Fig. 1: Detection of *mecA* gene among methicillin resistant *S. aureus* isolates. Four of the multidrug resistant *S. aureus* strains (SA1-SA4) that were also resistant to methicillin were tested for the presence of *mecA* gene that encodes methicillin resistance. The amplicons were separated on a 2% agarose gel, stained with ethidium bromide and visualized under UV transilluminator.

3.4. 16S rRNA gene sequencing and phylogenetic analysis

Phylogenetic trees were constructed using 16S rRNA gene sequences from each of the MDR pathogens from this study against the sequences of MDR strains from NCBI (Figure 2

). The phylogenetic trees revealed that the isolates formed a cluster with other MDR strains of the same species, but not with non-MDR strains or strains belonging to different species.

3.5. Isolation and morphological features of the phages

Figure 3 depicts transmission electron micrographs of all 5 phages, i.e., $\Phi\text{DMSA-2}$, $\Phi\text{DMSX-1}$, $\Phi\text{DMPA-1}$, $\Phi\text{DMEC-1}$, and $\Phi\text{DMPM-1}$. All phages possessed an isometric icosahedral capsid of varying sizes. The details of phage dimensions and their classification are given in Figure 3. The phages $\Phi\text{DMSA-2}$, ΦDMEC , and ΦDMPM exhibited a head size in the range 60-90 nm and tail of 200-240 nm long. These 3 phages were assessed to be belonging to the family *Siphoviridae*. The morphological characteristics of phage was examined and confirmed as phage belonging to the family *Siphoviridae*. On the other hand, phages ΦDMSX and ΦDMPA appeared to possess a bigger head size with 100-137 nm and a tail of 210-217 nm. Interestingly, the phage ΦDMSX for *S. xyloso* had a head with a triangular aspect, which was different from all other phages. ΦDMSX belongs to a group of "twort-like phages" under the sub family *Spounavirinae* of the family *Myoviridae*. Its tail measured about 210 nm showing conspicuous striations and terminate in a base plate with a set of spikes.

3.6. Host range

Four multidrug-resistant strains from each species were chosen for determining the *in vitro* lytic efficacy of the phages $\Phi\text{DMSA-2}$, $\Phi\text{DMSX-1}$, $\Phi\text{DMEC-1}$, $\Phi\text{DMPA-1}$, and $\Phi\text{DMPM-1}$ Table 3 shows the degree of lytic activity of all five phages against their specific host MDR isolates from each species. The results were scored as a clear zone of complete lysis (++) , partial lysis with turbidity (+) and no lysis (0). The phages against *S. aureus* ($\Phi\text{DMSA-2}$), *P. aeruginosa* ($\Phi\text{DMPA-1}$) and *E. coli* ($\Phi\text{DMEC-1}$) exhibited strong lytic activity and could completely lyse 3 of 4 (75%) tested strains. Importantly, no bacteriophage-insensitive mutants (BIM) were observed for this phage. The *S. xyloso* phage was able to completely lyse 1 strain (25%), partially lyse 2 strains (50%) and no lysis in the case of 1 strain (25%). The phage $\Phi\text{DMPM-1}$ against *P. mirabilis* showed only partial lysis of all 4 strains tested. The occurrence of bacteriophage-insensitive mutants (BIM) based on the growth of bacterial colonies within the plaque were noticed in the case of three phages ($\Phi\text{DMSX-1}$, $\Phi\text{DMEC-1}$ and $\Phi\text{DMPA-1}$).

3.7. Factors influencing the stability of the phages

The stability of phage lysates was tested in different storage conditions and period. The level of phage titre (10^8 pfu) did not decrease significantly ($P < 0.05$) after 3 month storage at all of the tested temperatures, i.e., 6 months at -20°C




Fig. 2: 16S rRNA gene sequence based phylogenetic analysis of the MDR pathogen isolates. PCR amplification of the 16S rRNA gene from the representative strains from each pathogenic species (A). 16S rRNA gene sequences from the MDR bacterial isolates were compared with those from known MDR pathogens of the same species. Multiple sequence alignment and phylogenetic trees were constructed using the bioinformatics tool MEGA5 (B). Circled isolates are from this study




Fig. 3: Electron micrographs of phages specific to the MDR pathogen isolates. Glutaraldehyde-fixed phage lysate was deposited on formvar carbon-coated copper grids and negatively stained with 1% phosphotungstic acid. TEM images were acquired on a Tecnai G Biotwin (Philips-Netherlands) transmission electron microscope. Using the scale from the image acquiring software, sizes of head and tail were measured

and 9 months at -40°C with glycerol. However, at room temperature, the titer was reduced 30% from 10^8 pfu/ml to 7×10^7 pfu/ml. When phages were exposed to a high temperature of 60°C for 15 minutes, phage titers decreased significantly up to 10^6 pfu/ml ($P < 0.05$). Phages were stable between pH range 6-9 and completely lysed at pH 2 and 4. Incubation at pH 4 and 37°C caused a 30% (7×10^7 pfu/ml) and 60% (4×10^7 pfu/ml) decrease in phage titre after 1 and 5 h of incubation, respectively.




Fig. 5:




Fig. 4:

4. Discussion

In this study, locally isolated phages lysed multi drug resistant bacterial isolates belonging to important pathogenic species from skin infections. Clinical samples collected from pyogenic skin infections were collected from a total of 114 patients. The highest prevalence of bacteria, i.e., 41 (48.80%) was recorded from abscess, followed by pyoderma, ulcers, cellulitis, wounds and diabetic foot. Existing literature has revealed that the general microbiota of human skin infections includes *S. aureus* as a highly

Table 1: Profile of pathogenic bacterial isolates from pyogenic skin infections

| Type of infection | Pathogenic bacterial isolates | | | | | TotalN (%) |
|--------------------------|-------------------------------|---------------------------|----------------------------|----------------------|------------------------|-------------------|
| | <i>S. aureus</i> N (%) | <i>P. mirabilis</i> N (%) | <i>P. aeruginosa</i> N (%) | <i>E. coli</i> N (%) | <i>S. xyloso</i> N (%) | |
| Abscess | 26 (30.95) | 9 (10.71) | 3 (3.57) | 3 (3.57) | 0 (0) | 41 (48.80) |
| Pyoderma | 8 (9.52) | 1 (1.19) | 2 (2.38) | 0 (0) | 0 (0) | 11 (13.09) |
| Ulcer | 7 (8.33) | 1 (1.19) | 1 (1.19) | 0 (0) | 0 (0) | 9 (10.71) |
| Cellulitis | 3 (3.57) | 1 (1.19) | 1 (1.19) | 0 (0) | 0 (0) | 5 (5.95) |
| Wound | 4 (4.76) | 1 (1.19) | 0 (0) | 0 (0) | 0 (0) | 5 (5.95) |
| Diabetic foot | 1 (1.19) | 1 (1.19) | 0 (0) | 2 (2.38) | 1 (1.19) | 5 (5.95) |
| Post-Operative Infection | 4 (4.76) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (4.76) |
| Folliculitis | 3 (3.57) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (3.57) |
| Burn Wound Infection | 1 (1.19) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1.1) |
| Total | 57 (67.85) | 14 (16.66) | 7 (8.33) | 5 (5.95) | 1(1.19) | 84 (100) |


Table 2: Antibiotic resistance of the bacterial pathogens from pyogenic infections

| Species | Antibiotic resistance N (%) | | | | | | | |
|------------------------------|-----------------------------|----------|----------------|----------|---------|---------|---------|---------|
| | Ak | Cf | Cd | E | M | Of | Ox | P |
| Gram-positive species | | | | | | | | |
| <i>S. aureus</i> (n=46) | 22 (48) | 18 (40) | 7 (15)* | 14 (31)* | 19 (41) | 19 (41) | 19 (41) | 19 (41) |
| <i>S. xyloso</i> (n=1) | R [#] | R | S [#] | R | S | R | R | R |
| Gram-negative species | | | | | | | | |
| <i>P. aeruginosa</i> (n=10) | 4 (40) | 10 (100) | 6(60) | 8 (80) | 6 (60) | 8 (80) | 6 (60) | 6 (60) |
| <i>E. coli</i> (n=4) | 2 (50) | 3 (75) | 2 (50) | 3 (75) | 3 (75) | 4 (100) | 3 (75) | 3 (75) |
| <i>P. mirabilis</i> (n=13) | 10 (77) | 6 (46) | 10 (77) | 7 (54) | 9 (69) | 11 (85) | 12 (92) | 11 (85) |

Ak, Amikacin; Cf, Ciprofloxacin; Cd, Clindamycin; E, Erythromycin; M, Methicillin; Of, Ofloxacin; Ox, Oxacillin; P, Penicillin G; Ac, Amoxicillin; Ca, Ceftazidime; Cs, Cefoperazone; Le, Levofloxacin; Tb, Tobramycin; Ce, Cephatoxime

#R=resistant, S=susceptible

*P=0.02

**Fig. 6:**

predominant species,¹⁹ but species from other genera such as *Pseudomonas*, *Enterococcus*, *Escherichia*, *Enterobacter*, *Klebsiella*, *Proteus*, *Acinetobacter*; and coagulase-negative *Staphylococcus* spp. are also commonly present.³

Nearly 40% of the *S. aureus* strains showed resistance to all major antibiotics available for Gram-positive bacteria during the period this study was conducted. The only other Gram-positive species, *S. xyloso*, was resistant to all tested antibiotics except clindamycin and methicillin. Among Gram-negative bacteria, 50-100% of all three species, *P. aeruginosa*, *E. coli*, and *P. mirabilis*, were resistant to all antibiotics tested except amikacin. Multidrug resistance among bacterial pathogens occurring in skin infections in India has been reported in a number of studies. These studies found that major pathogens such as *S. aureus*, *E. coli*, *P. aeruginosa* etc. were resistant (>60%) to major antibiotics including penicillin, erythromycin, co-trimoxazole, clindamycin, cefepime, and ciprofloxacin.²⁰ Even though Gram-negatives are most frequently encountered, *S. aureus* is of immense clinical significance due to its role in skin infections. In our study, 41% of the *S. aureus* isolates were resistant to methicillin. MRSA have become a major challenge worldwide with varied prevalence depending on geographic region.^{21,22} MRSA develop resistance through the acquisition of the *mecA* gene, which facilitates production of “penicillin-binding protein 2a” (PBP2a) that strengthens the cell wall and increases resistance to β -lactam antibiotics by blocking

Table 3: Host range of the bacteriophages against MDR bacterial strains

| | Bacterial isolates | Lytic activity of Phages | BIM* |
|---|-----------------------------|---------------------------------|-------------|
| Complete lysis (Figure 4) | <i>S. aureus</i> | Φ DMSA.2 | |
| | DMSA.1 | ++ | |
| | DMSA.2 | ++ | |
| | DMSA.3 | ++ | - |
| | DMSA.4 | - | |
| | <i>S. xylosus</i> | Φ DMSX.1 | |
| | DMSA.1 | ++ | |
| | DMSA.2 | + | |
| | DMSA.3 | - | + |
| | DMSA.4 | + | |
| Bacteriophage-insensitive mutant colony (Figure 5) | <i>P. aeruginosa</i> | Φ DMPA.1 | |
| | DMPA.1 | ++ | |
| | DMPA.2 | + | |
| | DMPA.3 | ++ | + |
| | DMPA.4 | ++ | |
| | <i>E. coli</i> | Φ DMEC.1 | |
| | DMEC.1 | ++ | |
| | DMEC.2 | ++ | |
| | DMEC.3 | - | + |
| | DMEC.4 | ++ | |
| Turbidity due to partial lysis; Several BIM colonies (Figure 6) | <i>P. mirabilis</i> | Φ DMPM.1 | |
| | DMPM.1 | + | |
| | DMPM.2 | + | |
| | DMPM.3 | + | |
| | DMPM.4 | + | |

the β -lactam binding site.²³ Penicillin-resistant strains of *S. aureus* predominate the nosocomial infections and currently only <5% of the *S. aureus* strains are penicillin-susceptible.²⁴

Biological and geographical relationship among MDR strains is generally studied using 16S rRNA gene sequences and allows sequence comparison among strains from different geographic regions. In the present study, each of the representative MDR pathogen species formed a close clade in the phylogenetic tree with other MDR strains. Horizontal transfer of antibiotic resistance genes in the environment is a continuous natural phenomenon. Thus, phylogenetic analysis of MDR strains provides important information about their geographic distribution and may therefore help devise better treatment strategies.²⁵

Phages against *S. aureus*, *P. aeruginosa* and *E. coli* exhibited highest lytic activity as evidenced by spot test. The phage against *P. mirabilis* was able to lyse all 4 strains but only moderately and no complete lysis was observed for any strain. In earlier studies, phages have been reported to display broad host range, killing different strains from the same species, e.g., phage Stau2 could lyse 80% of the *S. aureus* isolates obtained from hospitals in Taiwan.¹³

In another study, *E. coli* pathogenic strains EHEC, EPEC, ETEC, and UPEC were effectively lysed by a phage.²⁶ High selectivity and specificity of phages to their respective host bacteria provide a convenient yet effective way to eradicate bacterial pathogens both intracellular and otherwise in skin infections.

In our study, except for *S. aureus*, all other species produced bacteriophage insensitive mutants (BIMs). Even though phages have been successfully tested as alternative therapeutic agents in several human infections,²⁷ emergence of BIMs is a serious concern. The bacterial resistance to phages can occur through different mechanisms, e.g., restriction modification, abortive infection, and more commonly through mutations in phage receptor sites on the bacterial cell surface, preventing them from attachment. However, bacteriophage insensitivity is known to come at a cost for the host bacteria, i.e., the BIM trait makes the bacteria compromise with their performance in other traits resulting in slower growth, decreased virulence, and even diminished resistance to various antibiotics.²⁸

From the perspective of phage therapy in clinical medicine, stability of phages upon storage and implementation of appropriate storage conditions is

critical for a successful outcome. Storage stability of all four phages examined under different parameters showed that there was no significant decrease in the phage titre except at room temperature. Interestingly, only Φ DMSA-2 was stable for 9 months, the longest duration of storage as compared to the other phages. There are a few studies reporting the use phage as in hand sanitizer solutions and as disinfectants to sanitize operating rooms and medical equipment.²⁹ Further, a gel containing a cocktail of phages targeted nasal carriage of MRSA significantly reducing the incidence of MRSA transmission.^{18,30} Thus, our data showing remarkable stability of the phages in a variety of conditions is an important step forward in developing phage therapy for skin infections.

One of the serious concerns about the use of phage therapy in vivo is a strong antibody response which would clear the phages more quickly.³¹ To circumvent this problem, phages with different antigenicity or with low immunogenicity could be prepared. Other drawbacks of phages as therapeutic agents are their often-narrow host ranges and the fact that phages are not always lytic under certain physiological conditions. Further, phage therapy triggers release of endotoxins from the target pathogen due to widespread bacterial cell lysis. This occurs also when antibiotics are used, but it could be countered with regulated use of phages.

5. Conclusions

Predominant occurrence of clinically important, multidrug resistant bacterial pathogens in skin infections highlights the severity of the problem. Multidrug resistance among the majority of the bacterial isolates underscores the existing global problem with the current antibiotic therapies. Phages have special advantage for localized use in skin infections, because, unlike antibiotics, they penetrate deeper in an infected tissue rather than decrease rapidly in concentration below the surface. Importantly, in our recent study,¹¹ lytic efficacy of the phage Φ DMSA-2 against MRSA, was shown to significantly enhance the survival of mice in an in vivo skin excisional model. Thus, our study emphasizes the importance of need-based and locally isolated bacteriophages as potential alternative antimicrobial therapy.

6. Ethics

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institute and with the 1975 Helsinki declaration and its later amendments (revised in 2000) or comparable ethical standards. The study's experimental design and protocol were approved by the Ethics Committee at Bapuji Institute of Engineering and Technology.

7. Author Contribution

MNS: Conception, design, experimentation, data analysis and manuscript writing. MK: Experimentation, data analysis and manuscript writing. DA: Data analysis, manuscript writing.

8. Source of Funding

The corresponding author is grateful to Vision Group on Science and Technology (VGST), Govt. of Karnataka Secretariat, India for the facilities created through funding in the department of Biotechnology for research under the schemes Seed Money to Young Scientist for Research (SMYSR) and Centers of Innovative Science and Engineering Education (CISEE).

9. Conflict of Interest

The authors declare that they do not have any conflict of interest.

Acknowledgements

We are grateful to Hans-W Ackerman, Professor Emeritus, Laval University, Quebec, Canada and former Vice-President of International Committee on Taxonomy of Viruses (ICTV) for his generous help and support with electron microscopy and bacteriophage classification. We thank Skanda Life Sciences, Bengaluru for their lab facility. Lastly, Oral Microbiology Research Laboratory (SRUL 01/14), Kuwait University is acknowledged for the co-author M Karched's collaboration on this study.

References

1. Afsar FS. Skin infections in developing countries. *Curr Opin Pediatr.* 2010;22(4):459–66.
2. WHO. Epidemiology and management of common skin diseases in developing countries World Health Organization; 2005. Available from: <https://apps.who.int/iris/handle/10665/69229>.
3. Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. *Curr Opin Infect Dis.* 2016;29(2):109–15.
4. DiMeglio P, Perera GK, and FON. The multitasking organ: recent insights into skin immune function. *Immunity.* 2011;35(6):857–69.
5. Soong G, Paulino F, Wachtel S, Parker D, Wickersham M, Zhang D, et al. Methicillin-resistant Staphylococcus aureus adaptation to human keratinocytes. *mBio.* 2015;6(2):e00289–15.
6. Chang HH, Cohen T, Grad YH, Hanage WP, O'brien TF, Lipsitch M. Origin and proliferation of multiple-drug resistance in bacterial pathogens. *Microbiol Mol Biol Rev.* 2015;79(1):101–117.
7. Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. *Antimicrob Resist Infect Control.* 2018;7:58.
8. Hesse S, Adhya S. Phage Therapy in the Twenty-First Century: Facing the Decline of the Antibiotic Era; Is It Finally Time for the Age of the Phage? *Annu Rev Microbiol.* 2019;73:155–74.
9. Lusiak-Szelachowska M, Weber-Dabrowska B, Gorski A. Bacteriophages and Lysins in Biofilm Control. *Virology.* 2020;35(2):125–33.
10. Szafranski SP, Kilian M, Yang I, Wieden GB, Winkel A, Hegermann J, et al. Diversity patterns of bacteriophages infecting *Aggregatibacter*

- and Haemophilus species across clades and niches. *ISME J*. 2019;13(10):2500–22.
11. Shetru MN, Karched M, Agsar D. Locally isolated broad host-range bacteriophage kills methicillin-resistant *Staphylococcus aureus* in an in vivo skin excisional wound model in mice. *Microb Pathog*. 2021;152:104744. doi:10.1016/j.micpath.2021.104744.
 12. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol*. 1966;45(4):493–6.
 13. Hsieh SE, Lo HH, Chen ST, Lee MC, Tseng YH. Wide host range and strong lytic activity of *Staphylococcus aureus* lytic phage Stau2. *Appl Environ Microbiol*. 2011;77(3):756–61.
 14. Institute CaLS. Guidelines by CLSI/NCCLS - CLSI informational supplement. Approved standard M100-S15. Wayne, PA: CLSI; 2005.
 15. Bou G. Minimum inhibitory concentration (MIC) analysis and susceptibility testing of MRSA. *Methods Mol Biol*. 2007;391:29–49.
 16. Geha DJ, Uhl JR, Gustaferrero CA, Persing DH. Multiplex PCR for identification of methicillin-resistant staphylococci in the clinical laboratory. *J Clin Microbiol*. 1994;32(7):1768–72.
 17. Sauer P, Gallo J, Kesselova M, Kolar M, Koukalova D. Universal primers for detection of common bacterial pathogens causing prosthetic joint infection. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2005;149(2):285–8.
 18. Thompson JM, Gundogdu A, Stratton HM, Katouli M. Antibiotic resistant *Staphylococcus aureus* in hospital wastewaters and sewage treatment plants with special reference to methicillin-resistant *Staphylococcus aureus* (MRSA). *J Appl Microbiol*. 2013;114(1):44–54.
 19. Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev*. 2015;28(3):603–61.
 20. Sardana K, Manchanda V, Rajpal M, Garg VK, Chauhan DS. Bacterial pyoderma in children and therapeutic options including management of community-acquired methicillin resistant *Staphylococcus aureus*. *Int J Dermatol*. 2007;46(3):309–13.
 21. Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: A review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. *Can J Infect Dis Med Microbiol*. 2008;19(2):173–84.
 22. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. *Clin Infect Dis*. 2002;34(4):482–92.
 23. Ito T, Katayama Y, Asada K, Mori N, Tsutsumimoto K, Tiensasitorn C, et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2001;45(5):1323–36.
 24. Ladhani S, Garbash M. Staphylococcal skin infections in children: rational drug therapy recommendations. *Paediatr Drugs*. 2005;7(2):77–102.
 25. Sagova-Mareckova M, Ulanova D, Sanderova P, Omelka M, Kamenik Z, Olsovska J, et al. Phylogenetic relatedness determined between antibiotic resistance and 16S rRNA genes in actinobacteria. *BMC Microbiol*. 2015;15:81. doi:10.1186/s12866-015-0416-6.
 26. Manohar P, Tamhankar AJ, Lundborg CS, Nachimuthu R. Therapeutic Characterization and Efficacy of Bacteriophage Cocktails Infecting *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterobacter* Species. *Front Microbiol*. 2019;10:574. doi:10.3389/fmicb.2019.00574.
 27. Mattila S, Ruotsalainen P, Jalasvuori M. On-Demand Isolation of Bacteriophages Against Drug-Resistant Bacteria for Personalized Phage Therapy. *Front Microbiol*. 2015;6:1271. doi:10.3389/fmicb.2015.01271.
 28. Oechslin F. Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy. *Viruses*. 2018;10(7):351.
 29. O'Flaherty S, Ross RP, Meaney W, Fitzgerald GF, Elbreki MF, Coffey A. Potential of the polyvalent anti-*Staphylococcus* bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. *Appl Environ Microbiol*. 2005;71(4):1836–42.
 30. Mann NH. The potential of phages to prevent MRSA infections. *Res Microbiol*. 2008;159(5):400–5.
 31. Clark JR, March JB. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. *Trends Biotechnol*. 2006;24(5):212–8.

Author biography

Manjunath Nandihalli Shetru, Associate Professor & Head

Maribasappa Karched, Associate Professor  <https://orcid.org/0000-0001-8927-6617>

Dayanand Agsar, Professor & Vice Chancellor

Rangaswamy B E, Professor

Cite this article: Shetru MN, Karched M, Agsar D, Rangaswamy B E. *In vitro* lytic efficacy of bacteriophages against multidrug-resistant pathogenic bacterial species isolated from pyogenic skin infections. *Indian J Microbiol Res* 2022;9(1):14-23.